Development and validation of an integrated machine learning model for recurrence-free survival prediction in clear cell renal cell carcinoma.
Authors
Affiliations (6)
Affiliations (6)
- VIP Department, Affiliated Tumor Hospital of Xinjiang Medical University, Urumqi, Xinjiang, 830011, China.
- Department of Urology, The Central Hospital of Shaoyang, Shaoyang, Hunan, 422000, China.
- Imaging Center, Hunan Provincial People's Hospital, First Affiliated Hospital of Hunan Normal University, Changsha, Hunan, 410005, China.
- Urology Center, First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, 830054, China.
- Tumor Center, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, Xinjiang, 830001, China.
- VIP Department, Affiliated Tumor Hospital of Xinjiang Medical University, Urumqi, Xinjiang, 830011, China. Electronic address: [email protected].
Abstract
Integrated multimodal systems improve recurrence-free survival (RFS) prediction in surgically resected clear cell renal cell carcinoma (ccRCC) to overcome traditional model limitations. A total of 1284 patients were enrolled and divided into training (n = 738), internal validation (n = 317), and external test (n = 229). A machine learning (ML)-based model combined clinical data, radiomics signature (Rad-sign), and deep learning signature (DL-sign) to predict recurrence at 3-, 5-, and 7-year post-surgery. Radiomics features were extracted from CT images using ML, with the Rad-sign showing the best performance. A three-dimensional vision transformer (3D-ViT) for volumetric feature extraction outperformed ResNet models. Cox regression identified clinical features associated with RFS (p < 0.05). An optimal clinical-DL nomogram was chosen from 8 ML algorithms via 5-fold cross-validation. Clinical features alone had limited predictive power (external test AUC: 0.576, 95% CI: 0.472-0.672), while radiomics modeled by Naive Bayes (NB) performed better (AUC: 0.728). Rad-sign's C-index was 0.729, and the 3D-ViT model achieved an external test AUC of 0.846. The nomogram's AUCs for predicting 3, 5, and 7-year RFS post-surgery were 0.920, 0.935, and 0.938, with C-indices of 0.890 and 0.910, respectively. It effectively stratified risk groups, outperforming UISS and SSIGN via calibration and decision curve analysis. The ML-based clinical-DL model shows promise for accurate ccRCC RFS prediction, which may aid in personalized risk assessment and decision-making.